NDAORALSOLUTIONPriority Review
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
Priority Review
NYMALIZE (nimodipine) by R-Pharm US is calcium channel antagonists [moa]. First approved in 2013.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYMALIZE is an oral solution formulation of nimodipine, a dihydropyridine calcium channel blocker that reduces cerebral vasospasm following subarachnoid hemorrhage. It works by antagonizing calcium influx in vascular smooth muscle, improving cerebral blood flow and neurological outcomes in this acute neurological condition.
$0.066BPart D
Peak11.5 years to LOEProduct is at peak lifecycle stage with established market presence; brand team likely maintains stable size focused on market share retention rather than growth expansion.
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia
Started Feb 2021
Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1
36 enrolled
AIDS Dementia ComplexHIV Infections
Career Relevance
NYMALIZE represents a stable, mature commercial asset with limited growth trajectory but strong market protection through patent coverage and lack of competition. Career opportunities focus on market maintenance, key opinion leader engagement in neurocritical care, and payer relationship management rather than launch intensity.
Worked on NYMALIZE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.